WTSP – Aug. 16
With the help of a doctor at Moffitt Cancer Center, we're verifying whether that's true.
WTOL – Aug. 16
Dr. Fleming is the Chair and Program Director of the Department of Gastrointestinal Oncology at Moffitt Cancer Center. Prior to joining Moffitt, Dr. Fleming was a professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, where he served as Chief of Pancreas Surgery and Executive Director of Perioperative Services. Also posted to KITV, WFIE, WICZ,
Villages News – Aug. 15
“What would you do if you heard, ‘sorry, but you have cancer’,” asked Dr. Timothy Kubal, the guest speaker at the VHA-sponsored forum this week at the Eisenhower Recreation Center.
He is the Moffitt Cancer Center’s medical director of process excellence, and “focuses on continuous improvement of the patient experience.”
Tampa Bay Times – Aug. 15
Tampa General Hospital was ranked as Florida’s second-best hospital in the U.S. News and World Report’s 2018 Hospital Rankings released Tuesday, while Moffitt Cancer Center was named the country’s eighth-best cancer hospital.
Centro Tampa – Aug. 15
El Tampa General Hospital clasificó como el segundo mejor hospital de Florida en el Ranking de Hospitales 2018 de Noticias y del Informe Mundial de los EEUU. Publicado el martes, mientras que Moffitt Cancer Center fue nombrado el octavo mejor hospital de cáncer del país.
eCancer News – Aug. 15
"The goal of this trial was to find an alternative to cisplatin that would be as effective at controlling the cancer, but with fewer side effects," said Andy Trotti, M.D., of the Moffitt Cancer Center in Tampa, Florida, a lead investigator of the trial. "We were surprised by the loss of tumor control with cetuximab." Also posted to Breitbart, Longroom.com, United Press International, MedPage Today,
Naples Daily News – Aug. 14
The only other Florida hospital ranked in the top 10 for a specialty was Tampa’s H. Lee Moffitt Cancer Center and Research Institute, which ranked No. 8 for adult cancer hospitals.
Becker’s Hospital Review – Aug. 14
Cancer: … 8. Moffitt Cancer Center (Tampa, Fla.)
Forbes – Aug. 14
Besides melanoma, Iovance has phase 2 trials open testing TILs in head and neck cancer, cervical cancer, and non-small cell lung cancer (partnered with MedImmune), plus more trials through partnerships with the NCI, Moffitt Cancer Center, and MD Anderson Cancer Center testing TILs in combination with various immunotherapy drugs in melanoma and in other cancers.
Cancer Is One Worry Elephants Can Feel Free to Forget
Smithsonian.com – Aug. 14
Jessica Cunningham, a cancer biologist at the Moffitt Cancer Center who was not affiliated with the study, praised the “top notch” quality of the research. “They’re using all of the best experiments you can do to research this,” she says.
Healio – Aug. 14
Other hospitals ranked in the top 10 for cancer care are Memorial Sloan Kettering Cancer Center, Mayo Clinic in Rochester, Minn., Dana-Farber/Brigham and Women’s Cancer Center, Cleveland Clinic, Johns Hopkins Hospital, Seattle Cancer Care Alliance/University of Washington Medical Center, H. Lee Moffitt Cancer Center and Research Institute, UCSF Medical Center, and Hospitals of the University of Pennsylvania-Penn Presbyterian.
BusinessWire – Aug. 14
Among the twenty expert speakers sharing their respective experiences at bringing precision medicine, genetic medicine, and genetic testing into the daily care provided to their patients, will be: Howard L. McLeod, PharmD, Medical Director, Personalized Medicine Institute, Moffitt Cancer Center, on Precision Medicine in Oncology/Cancer Care
US News and World Report – Aug. 14
- Lee Moffitt Cancer Center and Research Institute, #8 in Adult Cancer Hospitals.
Medscape – Aug. 14
Slots six to ten were filled by Johns Hopkins Hospital, Baltimore, Maryland (80.3); Seattle Cancer Care Alliance/University of Washington Medical Center (78.5); H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida (76.6); the University of California, San Francisco, Medical Center (76.6); and the Hospital of the University of Pennsylvania, in Philadelphia (75.8).
WFTS – Aug. 18
“It's a naturally occurring radioactive element which is produced by the decay of uranium, found in the soil,” said Dr. Matthew Shabbath, a lung cancer epidemiologist at Moffitt Cancer Center.
83 Degrees Media – Aug. 13
The CDC and !p are partnering to recognize organizations that have demonstrated exemplary leadership in the 19-square-mile district bounded by Bearss Avenue, Busch Boulevard and Interstates 275 and 75. !p, which is dedicated to innovation in the area, includes as anchor institutions the University of South Florida, Florida Hospital Tampa, H. Lee Moffitt Cancer Center, Busch Gardens, James A. Haley Veterans’ Hospital, and RD Management, LLC, owner of University Mall.
Targeted Oncology – Aug. 13
David Sallman, MD, assistant member, Department of Malignant Hematology, Moffitt Cancer Center, explains the significance of the initial results from a recent phase 1B/2 trial combining APR-246 and azacitidine (Vidaza) in patients with TP53-mutant myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
Tampa Bay Business Journal – Aug. 13
Mariana Bugallo-Muros, vice president, chief human resources officer, Moffitt Cancer Center.
Nonahood News – Aug. 13
A gift from the Catherine McCaw-Engelman and Family Cancer Research Collaborative Fund made the purchase possible. The other CELLSEARCH system is at the Moffitt Cancer Center in Tampa.
Fortune – Aug. 10
The review article, by Kateřina Staňková of Maastricht University in the Netherlands, and Joel S. Brown, William S. Dalton, and Robert A. Gatenby at the Moffitt Cancer Center in Tampa, Florida, makes a well-argued case for upending the way we treat most cancers today.
Clinical Oncology News – Aug. 13
Dr. Lambertini and his colleagues analyzed patient data from five trials—PROMISE-GIM6, POEMS/SWOG S0230, Anglo Celtic Group OPTION, GBG-37 ZORO and a Moffitt Cancer Center–led trial—in which patients were randomly assigned to receive adjuvant or neoadjuvant chemotherapy with concurrent GnRHa or chemotherapy alone.
The Villages News – Aug. 12
The VHA will partner with the Moffitt Cancer Center at 5:30 p.m. Monday, Aug. 13 at Eisenhower Recreation Center to help educate residents regarding one of the scariest and most difficult decisions you may ever have to make.
OncLive – Aug. 10
Hatem Soliman, MD: If you’re going to use monotherapy fulvestrant, the patients whom you should select would be those who are similar to the FIRST and FALCON population, with low-burden, nonvisceral disease, or potentially de novo patients or those who have had a very long period of time between their adjuvant therapy, initial presentation, and their metastatic relapse.
Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.